Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders

Bibliography

• Rui L, Goodnow CC. Lymphoma and the control of B cell growth and differentiation. Curr Mol Med2006;6:291-308
   PubMed Web of Science ®Google Scholar
• Groom J, Mackay F. B cells flying solo. Immunol Cell Biol2008;86:40-6
   PubMed Web of Science ®Google Scholar
• D'arena G, Cascavilla N. Chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Leuk Lymphoma2007;48:1072-80
   PubMed Web of Science ®Google Scholar
• Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med2005;165:2337-44
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin2008;58:71-96
   PubMed Web of Science ®Google Scholar
• The Leukemia and Lymphoma Society. Chronic lymphocytic leukemia. Available from: http://leukemia-lymphoma.org [Last accessed 31 December 2008]
   Google Scholar
• Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum2008;58:15-25
   PubMed Web of Science ®Google Scholar
• Multiple Sclerosis Foundation. Available from: http://msfocus.org [Last accessed 31 December 2008]
   Google Scholar
• Debouverie M, Pittion-Vouyovitch S, Louis S, et al. Natural history of multiple sclerosis in a population-based cohort. Eur J Neurol2008;15:916-21
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol2005;23:4117-26
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol2006;24:3121-7
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol2006;7:379-91
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol2008;26:4579-86
   PubMed Web of Science ®Google Scholar
• van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood2006;108:3295-301
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Litchy S, Barton JH, et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol2003;21:1746-51
   PubMed Web of Science ®Google Scholar
• Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood2005;105:49-53
   PubMed Web of Science ®Google Scholar
• Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum2006;54:2793-806
   PubMed Web of Science ®Google Scholar
• Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med2008;358:676-88
   PubMed Web of Science ®Google Scholar
• Castillo J, Winer E, Quesenberry P. Newer monoclonal antibodies for hematological malignancies. Exp Hematol2008;36:755-68
   PubMed Web of Science ®Google Scholar
• Davis TA, Grillo-Lopez AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol2000;18:3135-43
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Meng C, Spigel DR, et al. Long-term followup of patients with follicular lymphoma (FL) treated with two years of maintenance rituximab: response to rituximab retreatment at progression. ASH Annual Meeting Abstracts 2006;108:4723
   Google Scholar
• Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med2001;344:68-9
   PubMed Web of Science ®Google Scholar
• Matteucci P, Magni M, Di Nicola M, et al. Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody. Blood2002;100:1104-5.
   PubMed Web of Science ®Google Scholar
• Teeling JL, French RR, Cragg MS, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood2004;104:1793-800
   PubMed Web of Science ®Google Scholar
• Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol2006;177:362-71
   PubMed Web of Science ®Google Scholar
• Beum PV, Lindorfer MA, Beurskens F, et al. Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J Immunol2008;181:822-32
   PubMed Web of Science ®Google Scholar
• Bleeker WK, Munk ME, Mackus WJ, et al. Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody. Br J Haematol2008;140:303-12
   PubMed Web of Science ®Google Scholar
• Cillessen SAGM, Mackus WJM, Castricum KCM, et al. Chemotherapy-refractory diffuse large B-cell lymphomas (DLBCL) are effectively killed by ofatumumab-induced complement-mediated cytoxicity. Blood (ASH Annual Meeting Abstracts) 2007;110:2346
   Web of Science ®Google Scholar
• Hagenbeek A, Plesner T, Johnson P, et al. HuMax-CD20, a novel fully human anti-CD20 monoclonal antibody: results of a phase I/II trial in relapsed or refractory follicular non-Hodgkin's lymphoma. Blood (ASH Annual Meeting Abstracts) 2005;106:4760
   Google Scholar
• Hagenbeek A, Plesner T, Walewski J, et al. HuMax-CD20 fully human monoclonal antibody in follicular lymphoma. First human exposure: early results of an ongoing phase i/ii trial. Blood (ASH Annual Meeting Abstracts) 2004;104:1400
   Google Scholar
• Hagenbeek A, Gadeberg O, Johnson P, et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood2008;111:5486-95
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepretre S, Pedersen LM, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood2008;111:1094-100
   PubMed Web of Science ®Google Scholar
• Coiffier B, Tilly H, Pedersen LM, et al. HuMax CD20 fully human monoclonal antibody in chronic lymphocytic leukemia. Early results from an ongoing phase i/ii clinical trial. Blood (ASH Annual Meeting Abstracts) 2005;106:448
   Google Scholar
• Coiffier B, Tilly H, Pedersen LM, et al. Significant correlation between survival endpoints and exposure to ofatumumab (HuMax-CD20) in chronic lymphocytic leukemia. Blood (ASH Annual Meeting Abstracts) 2006;108:2842
   Google Scholar
• Osterborg A, Kipps TJ, Mayer J, et al. Ofatumumab (HuMax-CD20), a novel CD20 monoclonal antibody, is an active treatment for patients with CLL refractory to both fludarabine and alemtuzumab or bulky fludarabine-refractory disease: results from the planned interim analysis of an international pivotal trial. Blood (ASH Annual Meeting Abstracts) 2008;112:328
   Google Scholar
• Ostergaard M, Baslund B, Rigby W, et al. Ofatumumab, a human CD20 monoclonal antibody, in the treatment of rheumatoid arthritis: early results from an ongoing, double-blind, randomized, placebo-controlled clinical trial [abstract 2086]. ACR/ARHP 2007 Annual Scientific Meeting, Boston, MA, USA, 6 - 11 November 2007
   Google Scholar
• Ostergaard M, Baslund B, Rigby W, et al. Efficacy of ofatumumab in rheumatoid arthritis (RA) patients with inadequate response to one or more DMARDs: 48 weeks follow up [abstract 373]. ACR/ARHP 2008 Annual Scientific Meeting, San Francisco, CA, USA, 24 – 29 October 2008
   Google Scholar
• Hallek M, Fingerle-Rowson G, Fink AM, et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL). Blood (ASH Annual Meeting Abstracts) 2008;112:325
   Web of Science ®Google Scholar
• Robak T, Moiseev SI, Dmoszynska A, et al. Rituximab, fludarabine, and cyclophosphamide (R-FC) prolongs progression free survival in relapsed or refractory chronic lymphocytic leukemia (CLL) compared with FC alone: final results from the international randomized phase III REACH trial. Blood (ASH Annual Meeting Abstracts) 2008;112:lba-1
   Web of Science ®Google Scholar
• Stashenko P, Nadler LM, Hardy R, et al. Characterization of a human B lymphocyte-specific antigen. J Immunol1980;125:1678-85
   PubMed Web of Science ®Google Scholar
• Robak T. Ofatumumab, a human monoclonal antibody for lymphoid malignancies and autoimmune disorders. Curr Opin Mol Ther2008;10:294-309
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Leonard JP, Coiffier B, et al. Initial safety and efficacy results of a second-generation humanized anti-CD20 antibody, IMMU-106 (hA20), in non-Hodgkin's lymphoma. Blood (ASH Annual Meeting Abstracts) 2005;106:2428
   Google Scholar
• Morschhauser F, Leonard JP, Fayad L, et al. Rituximab-relapsing patients with non-Hodgkins lymphoma respond even at lower doses of humanized anti-CD20 Antibody, IMMU-106 (hA20): phase I/II results. Blood (ASH Annual Meeting Abstracts) 2006;108:2719
   Google Scholar
• Liebman HA, Saleh MN, Abassi R, et al. Low-dose humanized anti-CD20 monoclonal antibody (MAb), veltuzumab, in adult immune thrombocytopenic purpura (ITP): initial results of a phase i/ii study. Blood (ASH Annual Meeting Abstracts) 2008;112:3412
   PubMed Web of Science ®Google Scholar
• Hutas G. Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies. Curr Opin Investig Drugs2008;9:1206-15
   PubMed Web of Science ®Google Scholar
• Genovese MC, Kain JL, Lowenstein MB, et al. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum2008;58:2652-61
   PubMed Web of Science ®Google Scholar